Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development Biotech Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer Biotech Investing
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 Biotech Investing
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy Biotech Investing
Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia Biotech Investing
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 Biotech Investing
Nextech3D.ai Reports Strong 20% Q2 Sequential Revenue Growth With Gross Margins of 88% For the Three Months Ended September 30, 2025 ("Q2 2026")
